Tag: vision after 60

  • First Human Age-Reversal Trial: What It Means for Those of Us Over 60

    First Human Age-Reversal Trial: What It Means for Those of Us Over 60

    What is the first human age-reversal trial, and does it work?

    Short answer: ER-100 from Life Biosciences is the first age-reversal treatment tested in people. It’s a single shot into one eye for glaucoma and a related optic nerve condition. Early results shared October 8, 2026 came from just 3 people over 8 weeks, and 2 of them improved on one vision test. It’s hopeful, but it’s an early start, not a cure.

    What would you do if a doctor told you there was a shot that could make the worn-out cells in your eye act young again?

    For years now every time I’d see “scientists reverse aging” in a headline I’d click on it and find out it was mice again. Always the mice. I started to figure those mice were going to outlive all of us.

    Well this fall that changed. Somewhere in this country a regular person with glaucoma, maybe somebody about our age, rolled up their sleeve, well not their sleeve, they got a shot in the eye, and became one of the first humans ever to try a treatment built to make old cells act young again.

    I’ll be honest, that gave me goosebumps. So I sat down with my coffee and read every bit of it I could find, and here’s what happened, plain and simple, and what it really means for folks our age.

    What happened in the first human age reversal trial

    On October 8, 2026, a Boston company called Life Biosciences shared the first results from the first human age reversal trial ever done. The treatment is called ER-100. Harvard geneticist David Sinclair co-founded the company, and you might know his name from his books and talks on aging.

    Three people with glaucoma got the lowest dose. After eight weeks all three handled it fine with no serious side effects, and two of the three did better on a standard eye test that measures how well you see light across your field of vision. The safety board liked what it saw enough to let them move up to a stronger dose.

    Think about that for a minute. These are people with glaucoma, a disease where the damage is supposed to be permanent, and two out of three saw better on their test after two months. It’s early and it’s small, but that’s the kind of thing that makes you sit up in your chair.

    What ER-100 actually does

    This isn’t a pill or a cream and you can’t buy it. It’s one shot into one eye, given in a clinic as part of the trial.

    The idea goes like this. As we get older the instructions that tell our cells which genes to turn on and off get scrambled up, kind of like an old cassette tape that’s been played too many times. The music is still on there, the tape just plays it wrong. ER-100 tries to clean up those instructions in the nerve cells of the eye so they work more like young ones again. It doesn’t change your DNA, it just helps the cell read it right.

    Patients take a common antibiotic called doxycycline for eight weeks to switch the treatment on, and when they stop taking it the treatment shuts off. I thought that was smart, it gives the doctors a way to turn it off if they need to.

    The young scientist behind it

    Here’s the part of the story I liked best. It all started with a young man named Yuancheng “Ryan” Lu. Age-related blindness runs in his family, and he’s said a great-aunt of his back in China was killed crossing a road because she couldn’t see the traffic coming. So when he was a student in Sinclair’s lab at Harvard he went after it, and he used this idea to bring sight back to old mice and mice with glaucoma. That work was published in the journal Nature in 2020 and it set the whole field on fire.

    MIT Technology Review just named him one of its Innovators Under 35, and I liked what he said about it. Sinclair has said he thinks people could live to 200, but Lu doesn’t buy that. He calls his own work more a proof that it can be done than a silver bullet.

    I appreciate a fella who doesn’t oversell his own work.

    Why start with the eyes

    Glaucoma is one of the leading causes of blindness for people our age, and once those eye nerve cells are damaged they don’t grow back on their own. There’s another condition being tested too called NAION, sometimes called a stroke of the eye, and right now there’s no approved treatment for it at all.

    The eye is also a safe place to start. It’s small and closed off, doctors can check your vision without cutting anything, and the treatment mostly stays where they put it.

    Here’s the catch

    I’m going to be straight with you because I’d want somebody to be straight with me.

    This was three people for eight weeks. That’s a start, not an answer. Two of three improving on one test is hopeful, but nobody can say yet if it lasts, if it helps everyday vision like reading or driving, or if it’s safe at higher doses. The results came from the company itself at a medical conference, and they haven’t been checked by outside scientists yet.

    Not everybody is cheering either. Paul Knoepfler, a stem cell scientist at UC Davis, called it a high-risk study and wrote that the treatment has been a bit oversold in the longevity world. I think it’s good to hear from the doubters too.

    And this is not a treatment to make your whole body younger. Nobody has shown that, in people, at all.

    What happens next

    The trial plans to treat 18 people ages 40 to 85 at four sites around the country, including Glendale, California and Charleston, South Carolina. The main results are expected around spring 2027, and they’ll keep checking on patients until 2032. Even if it all goes well, it would take years more testing before any doctor could offer it.

    What I’d do with this news today

    • Get your eyes checked. Glaucoma often sneaks up with no symptoms, and catching it early is still the best thing going.
    • Keep up with the treatment you have. If you already have glaucoma, don’t stop your drops or skip appointments waiting on something new.
    • Watch out for anybody selling “age reversal.” If somebody is selling a supplement, cream or shot that claims to do what ER-100 does, keep your wallet in your pocket. This treatment is only available inside the trial.
    • Ask your eye doctor. If you have glaucoma or have lost vision suddenly and you’re curious about the trial, your eye doctor can look up trial NCT07290244 on ClinicalTrials.gov with you.

    The Blue Zones Kitchen: 100 Recipes to Live to 100

    My take

    I reckon this is one of the more hopeful things I’ve read in a good while. Not because anybody is about to turn back the clock on us, but because smart people are finally testing whether worn-out cells can be brought back, and the first three people did fine. If it works, the first ones helped will be folks losing their sight to glaucoma, and that’s a pretty good place to start.

    While we wait on the scientists, there’s something you can do today. Try the simple floor test that may predict longevity. It takes a minute and it’ll tell you more about how you’re aging than any headline will.

    I’ll keep an eye on this one, no pun intended, and when the next results come out I’ll tell you what they show, good or bad.

    What do y’all think? Would you sign up for a trial like this one? Let me know in the comments.

    — Tom

    Common Questions

    What is the first human age reversal trial?
    It’s a small Phase 1 trial of ER-100, a gene therapy from Life Biosciences that tries to return eye nerve cells to a more youthful state in people with glaucoma or NAION.

    Did ER-100 reverse aging in humans?
    Not proven. In the first three people it was well tolerated for eight weeks, and two of three improved on a visual field test. No one has shown that it made human cells younger.

    Can I get ER-100?
    No. It’s only available inside the clinical trial, for people ages 40 to 85 with certain types of glaucoma or NAION.

    Who is David Sinclair?
    A Harvard Medical School geneticist who studies aging and co-founded Life Biosciences, the company testing ER-100.

    ER-100 is an experimental treatment and is not approved by the FDA. This article is general information, not medical advice. If you have glaucoma or sudden vision loss, see your eye doctor.

    About Tom Green

    Tom Green writes Well After 50. He was born in Pell City, Alabama, in 1962, and he’s a country boy and a true Southerner through and through. He’s just a regular, laid-back 64-year-old who keeps things simple. He shares what he learns about skincare, fitness and getting older, and what’s working for him. He’s also the author of A Practical Guide to Getting Older Without Giving Up on Yourself. Tom isn’t a doctor. He reads up on the research and passes along what’s useful, plain and simple.

    I’ve also mapped out some great tools on my new Tech for Independent Living After 50 page.